---
document_datetime: 2025-07-14 10:01:43
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/febuxostat-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: febuxostat-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1595873
conversion_datetime: 2025-12-24 18:14:54.867846
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Febuxostat Viatris

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------------------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA / EMA/VR/0000280136 | This was an application for a group of variations. | 10/07/2025                          |                                             | Annex II and PL                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| quality control testing sites); of the active substance, intermediate used in the (where specified in the technical Certificate of Suitability is manufacturer of a novel technical dossier) - Accepted A. ADMINISTRATIVE CHANGES and/or address of: a manufacturer quality control testing sites); of the active substance, intermediate used in the (where specified in the technical Certificate of Suitability is manufacturer of a novel technical dossier) - Accepted A. ADMINISTRATIVE CHANGES manufacturing sites for an finished product, packaging batch release, site where supplier of a starting material, mentioned in the dossier)*   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|